All In Biotech

Drug Trial Radar · NCT06517875

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Mar 16, 2027

Study completion Jan 31, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

Conditions

  • Primary Myelofibrosis
  • Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions

  • MomelotinibDrug

    Momelotinib will be administered orally.

  • LuspaterceptDrug

    Luspatercept will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with TI Response by Week 24Time frame: Up to Week 24

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ann Arbor, Michigan · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Seattle, Washington · Recruiting

  • GSK Investigational Site

    Vancouver, British Columbia, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Angers, France · Recruiting

  • GSK Investigational Site

    Brest, France · Recruiting

  • GSK Investigational Site

    Nice, France · Recruiting

  • GSK Investigational Site

    Nîmes, France · Recruiting

  • GSK Investigational Site

    Paris, France · Recruiting

  • GSK Investigational Site

    Poitiers, France · Recruiting

  • GSK Investigational Site

    Lyon, Rhône, France · Recruiting

  • GSK Investigational Site

    Lübeck, Germany · Recruiting

  • GSK Investigational Site

    Mannheim, Germany · Recruiting

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • GSK Investigational Site

    Jena, Thuringia, Germany · Recruiting

  • GSK Investigational Site

    Bologna, Italy · Recruiting

  • GSK Investigational Site

    Catania, Italy · Recruiting

  • GSK Investigational Site

    Florence, Italy · Recruiting

  • GSK Investigational Site

    Meldola FC, Italy · Recruiting

  • GSK Investigational Site

    Roma, Italy · Recruiting

  • GSK Investigational Site

    Milan, MI, Italy · Recruiting

  • GSK Investigational Site

    Badalona, Spain · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Las Palmas, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Málaga, Spain · Recruiting

  • GSK Investigational Site

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.